High school students rarely use e-cigarettes alone: A socio-demographic analysis of poly-substance use among adolescents in the USA.
Nicotine Tob Res. 2020 Feb 13;:
Authors: Gilbert PA, Kava CM, Afifi R
INTRODUCTION: Most adolescents reporting e-cigarette use have also used combustible tobacco; however, the extent to which they use other substances is less clear. This study assessed e-cigarette use with tobacco, alcohol, or cannabis and quantified the risk of poly-substance use among adolescents overall and by socio-demographic characteristics.
METHODS: Using 2017 Youth Behavioral Risk Factor Surveillance System data from adolescents (grades 9-12) with complete substance use information (n=11,244), we examined e-cigarette poly-use status (none [referent]; e-cigarettes only; or e-cigarettes + other substances). We estimated prevalence of substance use and modeled odds of e-cigarette use, alone or with other substances, by several socio-demographic characteristics. Analyses were completed in Stata version 15.1 using survey procedures to account for the complex survey design.
RESULTS: Approximately 12% of adolescents reported past 30-day e-cigarette use. Almost all (93%) e-cigarette users also reported other substance use; alcohol appeared most frequently in combinations. Odds of e-cigarette single use and e-cigarette poly-use (vs. no use) were higher for males and adolescents with lower grades (ORs 1.44-2.31). Racial/ethnic minorities had lower odds of e-cigarette poly-use than White peers (ORs 0.18-0.61), and bisexual (vs. straight) adolescents were more likely to be e-cigarette poly-users (OR=1.62). E-cigarette use increased from 9th grade (7%) to 12th grade (16%).
CONCLUSIONS: Poly-substance use is highly prevalent among adolescents who use e-cigarettes. Therefore, e-cigarette screening should include assessment of other substances, especially alcohol. Early and comprehensive prevention efforts to reduce e-cigarette and other substance use could have a substantial beneficial impact on population health over time.
PMID: 32052052 [PubMed – as supplied by publisher]
Source: ncbi 2